Mobia Medical, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Mobia Medical reported Q2 2026 revenue of $13.5M (up 102% YoY from $6.7M) with 83.2% gross margin. The company completed its IPO in May 2026, raising $134.0M net proceeds, bringing cash to $177.1M as of June 30, 2026. Despite revenue growth, net loss widened to $21.0M ($1.10 per share) due to 83% increase in operating expenses ($29.2M) driven by commercial expansion and higher R&D; FY 2026 revenue guidance of $54-56M implies 69-75% full-year growth.
Why this rating
IPO capital injection ($134M, ~182% of pre-IPO assets) and accelerating revenue growth (102% YoY) are material for $73.6M asset company. However, mounting losses ($38.8M H1 2026) and opex outpacing margin gains temper trajectory. Significance driven by major financing event and scale of growth relative to company size, not by current profitability.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.